GlassScriptPhysician profile
Yoon J Cho
NPI 1811094469
$11,166.21
in general payments reported to CMS, 2019-2025
22 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,500 · 2020: $1,391 · 2021: $1,677 · 2022: $1,025 · 2023: $1,295 · 2024: $1,722 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,572.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,681.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $2,674.21 | 2019-2025 | Tezspire, Farxiga |
| Amgen INC. | $1,655.47 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $1,308.13 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $967.01 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $288.64 | 2021-2022 | |
| Dexcom, INC. | $263.00 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Gilead Sciences, INC. | $208.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $198.53 | 2019-2025 | Capvaxive |
| Pfizer INC. | $173.87 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.28 | 2025 | |
| Astellas Pharma US INC | $142.01 | 2021-2025 | Veozah |
| Glaukos Corporation | $123.82 | 2025 | Photrexa Viscous and Photrexa |
| Arbor Pharmaceuticals, INC. | $86.93 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $79.09 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.46 | 2019-2022 | |
| Allergan, INC. | $43.58 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.64 | 2019 | |
| Amarin Pharma, INC. | $14.23 | 2021 | |
| Zest Holdings, LLC | $14.05 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoon Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.